Intrabases divergences in the mHealth era: a drug interaction investigation in an infectious-diseases hospital setting

Divergências intrabases na era mHealth: investigação de interações medicamentosas em um hospital de doenças infecciosas

Divergencias entre las bases en la era de la mHealth: investigación de las interacciones farmacológicas en un hospital de enfermedades infecciosas

Received: 06/14/2021 | Reviewed: 06/20/2021 | Accept: 11/10/2021 | Published: 11/14/2021

Abstract
Introduction: Information on potential drug interactions (PDI) are obtained from databases available on the web or through mobile healthcare applications (mHealth), and can prevent unfavorable clinical outcomes for patients. This study compared PDI information available in Micromedex® drug interaction checker, its web version and its mHealth app. Method: A cross-sectional study realized based on a retrospective review of drug prescriptions in a reference hospital in infectology in the Midwest Region of Brazil, 2018. We selected all prescriptions containing two or more drugs. Drugs were classified according to the first level of the Anatomical Therapeutic Chemical (ATC) classification, according to the route of administration and the number of drugs prescribed. PDIs were classified according to the severity system and four-level evidence classification system. Results: This study selected 72 patients, predominantly male, median age of 38 years, average length of stay of 15.8 days, and most diagnosed with HIV/AIDS. The most frequently prescribed anatomical groups according to ATC were digestive system and metabolism (22.1%) and frequently prescribed anatomical groups according to ATC were digestive system and metabolism (22.1%) and general anti-infectives for systemic use (21.6%). The average number of drugs per prescription was 10.8 (SD±6.7). The Micromedex® mHealth app found 381 PDIs while its web version detected 502 PDIs, with an average of 5.3 and 7.0 and frequency of 61.1% and 72.2%, respectively. According to the severity classification in mHealth and web versions, the following stood out, respectively: 221 and 321 severe; 139 and 149 moderate. The majority (>65%) of identified PDIs had their documentation classified as reasonable. Conclusion: Digital tools although they aid decision-making, are not unanimous and consistent in detecting such interactions.

Keywords: Drug prescriptions; Infectology; Mobile device; Drug interaction; Mobile health; Smartphone.

Resumo
Introdução: Informações sobre interações medicamentosas potenciais (IMP) podem ser obtidas em bases de dados disponíveis na web ou por meio de aplicativos móveis em saúde (mHealth), e podem evitar desfechos clínicos desfavoráveis aos pacientes. Este estudo comparou as informações de IMP disponíveis no verificador de interações medicamentosas Micromedex®, em sua versão disponível na web e seu aplicativo mHealth. Métodos: Realizou-se estudo transversal com base em revisão retrospectiva de prescrições de medicamentos em hospital de referência em infectologia da Região Centro-Oeste do Brasil, 2018. Seleccionamos todas as prescrições contendo dois ou mais
medicamentos. Os medicamentos foram classificados de acordo com o primeiro nível da classificação Anatomical Therapeutic Chemical (ATC), de acordo com a via de administração e o número de medicamentos prescritos. As IMP foram classificados de acordo com o sistema de gravidade e sistema de classificação de evidências em quatro níveis. 

Resultados: Foram selecionados 72 pacientes, com predominio do sexo masculino, mediana de idade de 38 anos, tempo médio de internação de 15.8 dias, e maioria com diagnóstico de HIV/AIDS. Os grupos anatômicos mais frequentemente prescritos segundo ATC foram aparelho digestivo e metabolismo (22.1%) e anti-infecciosos gerais para uso sistémico (21.6%). O número médio de fármacos por prescrição foi de 10.8 (DP±6.7). Encontrou-se 381 IMP em Micromedex® mHealth enquanto sua versão web detectou 502 IMP, com média de 5.3 e 7.0 e frequência de 61.1% e 72.2%, respectivamente. Segundo a classificação de gravidade na versão mHealth e web, destacaram-se respectivamente: 221 e 321 graves; 139 e 149 moderadas. A maioria (>65%) das IMP identificadas tiveram a sua documentação classificada como razoável. Conclusão: As ferramentas digitais, embora auxiliem na tomada de decisão, não são unânimes e concordantes na detecção de IMP.

Palavras-chave: Prescrições de medicamentos; Infectologia; Dispositivo móvel; Interação medicamentosa; Saúde móvel; Smartphone.

1. Introduction

In 2018 infectious diseases were responsible for more than 700 thousand hospitalizations in Brazil (Brasil, 2019). World Health Organization (WHO) data show that hospitalized patients tend to be in polypharmacy regimens- use of five or more comedications - which is considered one of the main risk factors for drug-drug interactions (DDI) (WHO, 2017a).

In this context, the identification of potential DDI (PDDI) is essential to avoid unfavorable clinical outcomes. Currently, information about PDDI, traditionally available on websites, can be also accessed through mobile health applications (mHealth). These tools make access to drug information easier and more versatile in the dynamic setting of bedside-care.

Annually, 44,000 to 98,000 deaths in the United States occur due to medication errors (Committee on Quality of Health Care in America, 2000). In this context, the dynamism provided by mHealth apps can contribute to the safe use of medicines.

Although mHealth apps could enhance contemporary health practice, important divergences in PDDI identification, severity classification and its clinical management have been shown by comparative studies (Pauly, et al., 2014).
In this context, we conducted a study on potential drug-drug interactions in prescriptions of hospitalized patients admitted into an infectious disease referral hospital and we compared PDDI information’s available in web drug interactions checker and their related mHealth apps.

2. Material and Methods

We conducted cross-sectional study based on a retrospective review of drug prescriptions, available in electronic medical records, from a referral infectology hospital in Center-West Region of Brazil, 2018. This study was approved by the Research Ethics Committee of State Hospital for Tropical Diseases Dr. Anuar Auad under registration CAAE. 81074117.8.0000.0034. Center-West Region of Brazil, 2018. This study was approved by the Research Ethics Committee of State Hospital for Tropical Diseases Dr. Anuar Auad under registration CAAE. 81074117.8.0000.0034. During the study period, there were 130 active beds in the institution. All hospitalized individuals were included, except those coming from day hospital beds, due to the short length of stay (<12 hours). We calculated mean, median, standard deviation for continuous variables and frequency for categorical variables.

A census was conducted on a date determined by electronic draw, data collection took place on a single day, in March 2018. We selected all prescriptions containing two or more medications. Individuals sociodemographic data and clinical characteristics were extracted from the SOUL MV Hospitalar® software (version 2000), which is the main software system comprising all the hospital’s patient data, using an own standard author form. Data were analyzed using the Epi info® platform (version 7.2.2.6 CDC, Atlanta Georgia - USA), Excel® (version 2013) and OpenEpi® (version 3.01). We calculated mean, median, standard deviation for continuous variables and frequency for categorical variables.

The drugs were classified according to the first level system (anatomical or pharmacological groups) of the World Health Organization's Anatomical Chemical Therapeutic Classification (ATC) (WHO, 2017b). Additionally, the drugs were classified according to the route of administration and the number of prescribed drugs: a) two to four medications; b) polypharmacy (5-9 comediations); c) excessive polypharmacy (≥10 comediations). The platform IBM Micromedex® Drug Interaction Checking (IBM Micromedex® Drug Interaction Checking, 2018) platform (Micromedex®) was elected for this study because of its widespread use in the literature and its recognized sensitivity and specificity in identifying PDDI (Jodlowski et al., 2011; Reis & Cassiani, 2011; Cedraz & Santos, 2014). Thus, the PDDI were classified according to the five-level severity system and the four-level documentation rating system, as described in Table 1.
Table 1 - Classification of potential drug-drug interactions regarding severity and quality of documentation, Micromedex® database

| Classification | Documentation | Severity |
|----------------|---------------|---------|
| Excellent      | Clinical studies have established the existence of interaction. |         |
| Good           | Documentation strongly suggests interaction, but robust studies are lacking. |         |
| Fair           | Available documentation is limited, but there is pharmacological evidence. |         |

| Classification | Severity |
|----------------|----------|
| Contraindicated| Drugs are contraindicated for concomitant use. |
| Major          | Interaction may be life-threatening and may require medical intervention to reduce or prevent serious adverse reactions. |
| Moderate       | Interaction may result in aggravation of the health problem or require change in treatment. |
| Minor          | Interaction may result in limited clinical effects. There may be increased frequency of side effects. |

Source: IBM Micromedex® Drug Interaction Checking (2018). Adapted by the authors.

3. Results

We selected 72 individuals and their respective drug prescriptions. Among these, 76.4% (n=55) were hospitalized in wards, 5.5% (n=4) in the emergency room and 18% (n=13) in an intensive care unit. The median age was 38 years, ranging from 1 to 82. Most individuals were male, 80% of them lived in urban areas and the average length of stay was 15.8 days (range 1 to 200). Approximately half of the individuals were hospitalized due to AIDS (Table 2).
Table 2 - Socio-demographic and clinical characteristics of individuals admitted to a referral infectology hospital, central-western Brazil, 2018.

| Variables                | Classification | N  | %  |
|--------------------------|----------------|----|----|
| Sex                      | Male           | 47 | 65.3|
|                          | Female         | 25 | 34.7|
| Age (years)              | ≤ 14           | 12 | 16.0|
|                          | 15 – 59        | 51 | 70.7|
|                          | ≥ 60           | 9  | 13.3|
| Marital status           | Married        | 16 | 27.6|
|                          | Single         | 38 | 65.5|
|                          | Othersb        | 4  | 6.9 |
| Race                     | White          | 6  | 8.5 |
|                          | Mixed / Black  | 65 | 91.5|
| Scholarity (years)       | < 3            | 11 | 36.7|
|                          | 4 – 7          | 6  | 20.0|
|                          | 8 – 10         | 3  | 10.0|
|                          | > 10           | 10 | 33.3|
| Diagnosis (CID 10)       | AIDS           | 33 | 45.8|
|                          | Pneumonia      | 8  | 11.1|
|                          | Influenza      | 9  | 12.5|
|                          | Tuberculosis   | 3  | 4.2 |
|                          | Dengue         | 3  | 4.2 |
|                          | Venomous animals| 3 | 4.2 |
|                          | Othersf       | 13 | 18.1|

a Missing data from 14 individuals.
b Others, Divorced: 3; Widower: 1.
c Missing data from 1 individual.
d Missing data from 42 individuals.
e International Classification of Diseases (ICD-10), WHO 2008; B20-B24: Human Immunodeficiency Virus Disease; J12-J18: Pneumonia; J09-J11: Influenza; A15: Respiratory tuberculosis; A91: Haemorrhagic Fever Due to Dengue Virus; T63: Toxic Effect of Venomous Animal Poison.
f Others, B41: Paracoccidioidomycosis; B55: Leishmaniasis; A30: Leprosy; A41: Other septicemia; A86: Viral Encephalitis; J43: Emphysema; J96: Respiratory failure; K70: Alcoholic hepatitis; L03: Cellulitis; L10: Pemphigus Vulgaris; R59: Localized swelling of lymph nodes.

Source: Authors.

An overall of 779 medications were prescribed, with an average of 10.8 (SD ± 6.7) drugs per prescription (range 2 to 30). Most of them were administered intravenously (~ 60%). Among the prescribed drugs, there were 126 distinct active substance that were classified into 11 ATC groups, of which 86% (n=669/779) were classified in four groups (A, B, J and N) (Table 3).

Polypharmacy was identified in more than 80% of prescriptions (p<0.000002), with a higher frequency among young / adults people aged 15 to 59 years with a frequency of 84.3% (95%CI 72.0-91.8%), followed by 83.3% (95% CI 55.2-95.3%) among children and in 77.8% (95% CI 45.3-93.7%) among elderly individuals (p=0.98). The prevalence of excessive polypharmacy (≥ 10 comedication) was 45.8% (95% CI 34.8-57.3%) and its occurrence was also observed in all age groups, affecting 25% of children, 49% of young/adults people and 55.5% of the elderly; (p=0.57) (Table 3).
Table 3 - Characteristics of drug prescriptions from patients admitted to a referral hospital in infectology, central-western Brazil, 2018.

| Variable                      | N   | %  |
|-------------------------------|-----|----|
| **Prescribed drugs**          |     |    |
| 2 – 4                         | 12  | 16.7|
| 5 – 9                         | 27  | 37.5|
| ≥10                           | 33  | 45.8|
| **Polypharmacy, ≥ 5 medicines** |     |    |
| Child                         | 10  | 16.7|
| Youth / Adult                 | 43  | 71.6|
| Elderly                       | 7   | 11.7|
| **Administration Routes a**   |     |    |
| IV                            | 464 | 59.6|
| VO                            | 173 | 22.2|
| Others*                       | 138 | 18.2|
| **Classification ATC b**      |     |    |
| A (Digestive system and Metabolism) | 172 | 22.1|
| B (Blood and Hematopoietic organs) | 167 | 21.4|
| J (Anti-infective agents for systemic use) | 168 | 21.6|
| N (Nervous system)            | 162 | 20.8|
| Others**                      | 110 | 14.1|

a IV: intravenous; VO: oral;
*Others, VE: enteral; SC: subcutaneous; IM: intramuscular.

b Classificacão Anatomical Therapeutic Chemical (ATC), WHO 2017.

**Others, C: Cardiovascular system; R: Respiratory system; H: Hormones for systemic use; M: Musculoskeletal system; D: Dermatological; G: Genitourinary system and sex hormones; P: Antiparasitic Products; V: Several.

Source: Authors.

Among 779 most commonly prescribed drugs from 126 active substances, sodium chloride and dipyrone were used by more than 80% of study participants (Table 4). We could not find any information about dipyrone and bromopr, the second and fourth most commonly medication prescribed, in the mHealth version of Micromedex®. Dipyrone and Bromopride are widely prescribed in Brazil, unlike most foreign countries, including the United States.

Table 4 - Most prescribed active substance among patients admitted to a referral infectology hospital, central-west Brazil, 2018.

| Active substance atraction | ATC Classification                                      | Individuals |
|---------------------------|---------------------------------------------------------|-------------|
| Sodium Chloride           | B05 - Blood substitutes and infusion solutions.         | 63          | 87.5 |
| Dipyrone                  | N02 – Analgesics.                                       | 58          | 80.5 |
| Dextrose                  | B05 - Blood substitutes and infusion solutions.         | 44          | 61.1 |
| Bromoprider               | A03 - Antispasmodic, anticholinergic and propulsive agents. | 37          | 51.4 |
| Ondansetron               | A04 - Antiemetics and antinauseants.                    | 33          | 45.8 |
| Sulfamethoxazole/Trimethoprimc | J01 - Antimicrobials for systemic use.                | 28          | 38.8 |
| Omeprazole                | A02 - Antacids and drugs for the treatment of peptic ulcer. | 28          | 38.8 |

a Active ingredients with a prescription frequency greater than 30% were selected.
b Data presented in decreasing form, the frequency of individuals who were prescribed the presented active substance.
c Sulfamethoxazole/Trimethoprim.

Source: Authors.
Analysis of Potential Drug-Drug Interactions

In this study analyzed prescriptions, at least one PDDI was found in 73.6% (n=53) of its total. From a total of 505 PDDIs, 75% (n=378) represents the intersection of identified ones in both Micromedex® versions. The web and mHealth version individually identified 502 and 381 PDDI, respectively. The PDDI average per prescription varied according to database version, being 7 (Dp±8.3) in web version and 5.3 (Dp ± 6.8) in mHealth version (p=0.52).

Among the 126 distinct active substance identified in this study, five of them (tenoxicam, ringer lactate, dipyrrone, nitrazepam and bromopride) were not available in the mHealth database, resulting in 124 PDDI, classified as contraindicated (n=11), major (n=103), moderate (n=10) that could not be detected by this version. In contrast, three severe PDDI, related to the combination of codeine-acetaminophen with comedication, were uniquely identified by mHealth app.

The severity rating showed that more than 60% of PDDI were contraindicated or severe and most of them (> 65%) were classified with documentation rated as reasonable (Figure 1). Figure 1 illustrates PPIs classified as severe, with frequency ≥0.6%, represented by constantly prescribed drugs. The arrows indicate IMP between the communicating parts. Bold are drugs with high frequency of IMP, which are only in the web version database., are they: Trimethoprim+Sulfamethoxazole : SXT; Rifampicin, Isoniazid and Pyrazinamide: RHZ.
There were 31 types of ART-related-PDDIs, the most common of them were found between dipyrone and the combination of tenofovir + lamivudine 1.4% (n=7/502).

4. Discussion

Our study analyzed drugs prescribed to individuals admitted to a reference hospital in infectology in the central-west of Brazil in order to investigate the occurrence of PDDI but also their information provided by two different versions (web and mHealth app) of the same database. Most of the participants in this study were young people or adults, who were in use of analgesics and antimicrobials, and half of the overall investigated population were individuals living with HIV/AIDS. More than 80% of individuals were under polypharmacy (p<0.01) and a prevalence of 73.6% of PDDI was identified.
Two versions of the Micromedex® database were used in order to identify and classify PDDI and important differences among those data were detected. These differences are mainly explained by the lack of information in the mHealth version on interactions involving the drugs dipyrone, bromopride, tenoxicam, nitrazepam and ringer lactate solution. In this setting, the mHealth version of Micromedex® was in disadvantage, since it did not got updates that contemplated information related to drugs commonly used in Brazil.

Dipyrone, the second most prescribed drug in our study, was identified in 76 PDDIs comediations pairs, about 87% of which were classified as severe. Dipyrone relevant clinical data could not be evaluated in the mHealth version scenario since this application not presented this drug in the available list.

Dipyrone is classified as a non-steroidal analgesic and anti-inflammatory drug (NSAID) and its effects as analgesic and antipyretic are unquestionable (Rang, et al., 2007). In Brazil dipyrone is included in the list of over-the-counter drugs (OTC) (ANVISA, 2020). However, safety information about the use of this medicine diverges, mainly because of the rare but serious adverse reactions such as aplastic anemia, Stevens-Johnson syndrome, toxic epidermal necrosis and agranulocytosis (Magni, et al., 2010).

Drug interactions related to bromopride, which could not be identified in the mHealth version, accounted for 9% (n=44) of total PDDI identified, 10 of them were considered contraindicated and 34, severe; both due to the risk of extrapyramidal reactions. The incidence of these reactions may be even higher when intravenous doses of bromopride are required, a warning alert, since more than a half of the drugs analyzed in this study were administrered by this route (Tonini, et al., 2004).

We highlighted that 116 antimicrobial-related-PDDI were identified in both versions of Micromedex® database which is a relevant event since the study setting was a referral infectology hospital. The most common antimicrobial-related-PDDIs were: sulfamethoxazole + trimethoprim (6.8%), azithromycin (4.8%) and rifampicin + isoniazid + pyrazinamide (4.6%). Yet, among those, severe PDDI identified were: azithromycin and fluconazole, azithromycin and ondansetron as well as sulfamethoxazole + trimethoprim and fluconazole, which were related to the risk of ventricular arrhythmias (QT interval prolongation) and ventricular fibrillation (Roden, et al., 2016).

It is worth highlight that azithromycin, among others antimicrobials, show electrophysiological effects similar to class III antiarrhythmic drugs (MARTINS et al., 2015) and fluconazole may prolong the QT interval, either directly or by inhibiting the hepatic metabolism of other agents that have direct action under this signal, such as atazanavir an antiretroviral drug involved in treatment of HIV infections (Molloy, et al., 2018).

About a half of the analyzed population was living with HIV/AIDS and almost 20% of individuals were on antiretroviral therapy (ART). In these setting, DDI may be an adjuvant factor in ART failure and an important cause of prejudice in treatment adherence (Molas, et al., 2018). The most frequent ART-related interaction of dipyrone and the combination of tenofovir + lamivudine 1.4% (n = 7/502) is related to the risk of renal failure, so patients should be adequately monitored for glomerular filtration rate (GFR), especially patients with GFR> 60 mL /min. Additionally, it is noteworthy that this PDDI could not be detected in the mHealth version (Machado, et al., 2014).

Monitoring ART-related-PDDIs is essential to improve the treatment of people living with HIV (PLHIV) (BRASIL, 2013). In this study, information provided by The Micromedex® web version indicated that all patients on ART had at least one interaction associated with antiretroviral drugs, while the mHealth version showed at least one ART-related-PDDI in 70% of prescriptions. Although the present study was conducted with prescriptions of hospitalized patients, where the chances of self-medication are minimized, it was found that the scenario regarding the occurrence of PDDIs is not more optimistic than that in an outpatient treatment setting, whose PDDIs prevalence varied from 23.6% to 52.2% according studies conducted in different regions of Brazil (Cascao, et al., 2017; Santos, et al., 2016).
The majority of participants underwent to the main risk factor for PDDIs since according to the literature, polypharmacy is the main risk factor for drug interactions (Monegat et al., 2014). Approximately 80% of the individuals in our study received prescriptions with 5 or more medications, and a half of the young and adults individuals received prescriptions containing 10 or more concomedications (excessive polypharmacy).

This study innovates since it brings highlights to intrabases divergences in the mHealth era through comparative information about PDDIs in different versions (mHealth and web) of a largely database (Micromedex®) applied in the literature. In addition, the present study also contributes in a better comprehension of the occurrence of PDDIs in hospitalized patients in a infectious diseases scenario, an unusual theme in the PDDIs investigation setting. Our study presents as its main limitation the impossibility of verifying if, in fact, such identified PDDIs occurred in clinical practice, though we did not have the propose to investigate it, since patient follow-up was not within the scope of this study.

Access to computerized databases, electronic prescriptions and alert programs are mechanisms of remarkable importance for the prevention and management of drug interactions (Correr & Otuki, 2013). However, it is necessary to standardize the contents of these databases and their different versions, so that any doubts on the appropriate clinical management are properly addressed.

5. Conclusion

This study demonstrated a high frequency of polypharmacy and a high frequency of contraindicated and severe pDDIs in prescriptions of hospitalized patients at a referral hospital in infectious diseases, Center-West Region of Brazil. Despite the clear advantages related to the versatility, mobility and optimization in the use of Micromedex® mHealth version in clinical practice, we have identified that pDDIs information related to frequently prescribed drugs in Brazil, such as dipyrone and bromopride, was only available in the web version of the database.

References

Cascao, P. C. (2017). Interacções medicamentosas potenciais associadas à Terapia Antirretroviral. Dissertação. Dissertação de Mestrado, Faculdade de Medicina UFG, Goiânia, Brasil.

Cedraz, K. N. & Santos, M. C. J. (2014). Identificação e caracterização de interações medicamentosas em prescrições médicas da unidade de terapia intensiva de um hospital público da cidade de Feira de Santana, BA. Sociedade Brasileira de Clínica Médica, 2 (1), 12. http://files.bvs.br/1679-1010/2014/v12n2/a4178.pdf

Correr, J. & Otuki, M. A. (2013). Prática Farmacêutica na Farmácia Comunitária (1a ed.). Porto Alegre: Artmed.

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., Shitsuka, R. (2018). Metodologia da Pesquisa Científica. Núcleo de Tecnologia Educacional, Universidade Federal de Santa Maria, Santa Maria, RS. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1

IBM. (2019). Micromedex® Drug Interaction Checking (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. http://www.micromedexsolutions.com

Institute of Medicine (US) Committee on Quality of Health Care in America, Kohn, L. T., Corrigan, J. M., & Donaldson, M. S. (Eds.). (2000). To Err is Human: Building a Safer Health System. National Academies Press (US).

Jodlowski, T. Z., Patel, P. N., Maische, N. M., Mildvan, D. (2011) Comparison of online drug interaction databases to evaluate antiretroviral medication interactions. Pharmacotherapy Journal, 31 (10), 312. Retrieved from: http://e-lactancia.org/media/papers/Metoprolol-BuprenorfinaBF-Pharmacother2011.pdf

Magni, A. M., Scheffer, D. K., Bruniera, P. (2011) Comportamento dos antitérmicos ibuprofeno e dipirona em crianças febris. Jornal de Pediatria, 87(1), 36-42.

Machado, J. A. E., Morales, C. D. P., Hoyos, V. S. (2014). Frecuencia de potenciales interacciones medicamentosas entre antirretrovirales y otros grupos farmacológicos en pacientes colombianos. Investigaciones Andinas, 16(28), 910-920. http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0124-81462014000100055&lng=en&tlng=es

Martins, J. M., Figueiredo, T. P., Costa, S. C., Reis, A. M. M. Medicamentos que podem induzir prolongamento do intervalo QT utilizados por idosos em domicílio. Ciência Farmacêutica Básica Aplicada. 2015; 32 (2): 297-305.
Molas, E., Luque, S., Retamero, A., Echeverría-Esna! D., Guelar, A., Montero, M., Guerri, R., Sorli, L., Lerma, E., Villar, J., & Knobel, H. (2018). Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team. HIV clinical trials, 19(1), 1–7. https://doi.org/10.1080/15284336.2017.1404690

Molloy, S. F., Bradley, J., Karunahan, N., Mputu, M., Stone, N., Phulusa, J., Chawinga, C., Gaskell, K., Segula, D., Ming, D., Peirse, M., Chanda, D., Lakhi, S., Loyse, A., Kanyama, C., Heyderman, R. S., & Harrison, T. S. (2018). Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis. AIDS (London, England), 32(15), 2259–2261. https://doi.org/10.1097/QAD.0000000000001961

Monegat, M., Sermet, C., & Rococo, E. (2014). Polypharmacy: Definitions, Measurements and stakes involved in review of literature and measurement test. Questions d’économie de la santé 204 (20), 1-8.

National Health Surveillance Agency [Agência Nacional de Vigilância Sanitária - ANVISA]. (2020). Farmacovigilância Bulletin No. 9 [Boletim de Farmacovigilância n°9]. Brasília. Retrieved from: https://www.gov.br/anvisa/pt-br/arquivos-noticias-anvisa97json-file-1

Pauly, A., Wolf, C., Busse, M., Strauß, A. C, Kreh, S., Dorje, F., & Friedland, K. (2015). Evaluation of eight drug interaction databases commonly used in the German healthcare system. European Journal of Hospital Pharmacy, 22(3), 165-70. doi:10.1136/ejhpharm-2014-000561

Pereira, A. S., Shiotsuka, D. M., Parreira, F. J., & Shiotsuka, R. (2018). Metodologia da Pesquisa Científica. Núcleo de Tecnologia Educacional, Universidade Federal De Santa Maria, Santa Maria, RS. https://repository.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1

Rang, H. P., Dale, M.M, Ritter, J. M., Flower, R. J. (2007). Farmacos antiinflamatórios e immunossupressores. Elsevier.

Reis, A. M. M. & Cassiani, S. H. B. (2011) .Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics, 66(1), 9-15. Retrieved from: https://doi.org/10.1590/S1807-59322011000100003.

Rodén, D. M. (2016). Predicting drug-induced QT prolongation and torsades de pointes. The Journal of physiology, 594(9), 2459–2468. https://doi.org/10.1113/JP270526

Santos, W. M., Secoli, S., & Padoin, S. Potenciais interações de drogas em pacientes de terapia antirretroviral. Rev. Latino-Am. Enfermagem. 2016;24:2832.

Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G. R., & De Ponti, F. (2004). Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Alimentary pharmacology & therapeutics, 19(4), 379–390. https://doi.org/10.1111/j.1365-2036.2004.01867.x

World Health Organization [WHO]. (2017a). Anatonic Therapeutic and Chemical Classification of Drugs. http://www.whocc.no/atcddd.

World Health Organization [WHO]. (2017a). Medication Without Harm. Who Global Patient Safety Challenge. file:///C:/Users/Robert/AppData/Local/Temp/WHO-HIS-SDS-2017.6-eng.pdf